

Administration of Infusion Medications

Effective July 1, 2017

Beginning July 1, 2017, Blue KC will implement a medical policy to require administration of the following medications in the most cost-effective site of care that is clinically appropriate for a member's condition. This means a member must begin receiving treatment at his or her home, physician's office or an infusion clinic, unless the hospital outpatient facility accepts a comparable rate to these alternative care sites. Medications delivered in these care settings are safe, clinically effective and less expensive for our members.

- Bivigam – IVIG
- Carimune, Gammagard – IVIG
- Flebogamma – IVIG
- Gamastan – IVIG
- Gamastan S/D – IVIG
- Gammagard – IVIG
- Gammaked, Gammunex – IVIG
- Gammaplex – IVIG
- Hizentra – IVIG
- Hyqvia – SCIG
- Octagam – IVIG
- Privigen – IVIG
- Prolia – denosumab
- Remicade – infliximab
- Tysabri – natalizumab

This requirement will become effective when the member's prescription drug prior authorization expires. Affected members will be notified of these changes by letter and will receive a call to remind them as the expiration date nears, but we encourage them to talk to their doctor and identify an alternative location as soon as possible.